Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

FDA application actionNovember 16, 2023

Pembrolizumab

Approved submission · SUPPL 143

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionNovember 15, 2023

Omeprazole

Approved submission · SUPPL 14

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionNovember 15, 2023

Omeprazole

Approved submission · SUPPL 19

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionNovember 15, 2023

Omeprazole

Approved submission · SUPPL 21

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionNovember 8, 2023

Tirzepatide

Approved submission · ORIG 1

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionNovember 7, 2023

Pembrolizumab

Approved submission · SUPPL 148

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 31, 2023

Pembrolizumab

Approved submission · SUPPL 144

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 31, 2023

Pembrolizumab

Approved submission · SUPPL 145

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 11

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 13

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 14

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 6

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 7

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 8

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 27, 2023

Sirolimus

Approved submission · SUPPL 9

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 23, 2023

hydrochlorothiazide

Approved submission · SUPPL 22

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 23, 2023

hydrochlorothiazide

Approved submission · SUPPL 3

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 23, 2023

hydrochlorothiazide

Approved submission · SUPPL 24

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 23, 2023

Pembrolizumab

Approved submission · SUPPL 142

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 20, 2023

hydrochlorothiazide

Approved submission · SUPPL 30

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 20, 2023

hydrochlorothiazide

Approved submission · SUPPL 32

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 16, 2023

Pembrolizumab

Approved submission · SUPPL 139

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 12, 2023

Pembrolizumab

Approved submission · SUPPL 138

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →
FDA application actionOctober 11, 2023

Omeprazole

Approved submission · SUPPL 56

A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.

Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence

Inspect the source record →